Antilung cancer effect of WT1-specific cytotoxic T lymphocytes

Masanori Makita, Akio Hiraki, Taichi Azuma, Akihiro Tsuboi, Yoshihiro Oka, Haruo Sugiyama, Shigeru Fujita, Mitsune Tanimoto, Mine Harada, Masaki Yasukawa

Research output: Contribution to journalArticlepeer-review

64 Citations (Scopus)


We and other groups have recently reported that CTLs that specifically recognize a peptide derived from WT1 lyse leukemia cells in a HLA class I-restricted manner. Because WT1 is expressed in various solid tumors as well as in leukemic cells, we investigated whether WT1-specific CTLs can also inhibit the growth of lung cancer by examining their cytotoxic activity against lung cancer cell lines in vitro and their inhibitory effect on the growth of human lung cancer cells engrafted into nude mice. The WT1 transcript was detected in most of the lung cancer cell lines examined. A WT1-specific, HLA-A24-restricted CTL clone (designated TAK-1) exhibited cytotoxicity against lung cancer cell lines bearing HLA-A24 but did not lyse cells lacking this HLA. This suggests that the target antigen for TAK-1 on HLA-A24-positive lung cancer cells is the naturally processed WT1 peptide. Adoptive transfer of TAK-1 into nude mice that had been engrafted with a HLA-A24-positive lung cancer cell line resulted in inhibition of cancer cell growth and prolonged survival. These findings strongly suggest that WT1 is a universal tumor-associated antigen and that WT1-targeting immunotherapy offers a potentially effective treatment option for lung cancer as well as leukemia.

Original languageEnglish
Pages (from-to)2626-2631
Number of pages6
JournalClinical Cancer Research
Issue number8
Publication statusPublished - 2002

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Antilung cancer effect of WT1-specific cytotoxic T lymphocytes'. Together they form a unique fingerprint.

Cite this